Expert Neurology Panel Discusses Advances in Multiple Sclerosis Therapies

Share Article

Neurologists on MedPredict’s exclusive thought leader panel are cautiously optimistic about new oral disease modifying agents coming to market, but due to uncertainty about long-term safety, they see these as second-line agents and still await major breakthroughs for the treatment of MS.

Forcing panelists to rank the agents helps us move beyond a theoretical discussion into a reality check on what they really want to use in their practice.

MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report entitled “Thought Leader Insight & Analysis: Multiple Sclerosis,” designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for diagnostics and treatments in this disease area.

“In this report, our panel of experts describes the clinical progress of the most interesting candidates in the pipeline,” according to Jeff Berk, MedPredict’s president and lead author. “For this iteration of our ongoing thought leader discussions, we asked our panelists to engage in a thought exercise with us. The purpose was to designate their ‘fantasy formulary,’ comprised of the key therapeutics currently in the development pipeline they want to see available for use in the prevention/treatment of MS. Forcing panelists to rank the agents helps us move beyond a theoretical discussion into a reality check on what they really want to use in their practice.”

While Bayer Schering/Genzyme’s Campath (alemtuzumab) and Novartis/Mitsubishi Tanabe Pharma’s Gilenia (fingolimod) received the most mentions from our panel, the research reveals interest in multiple mechanisms, with no clear runaway favorite and no broadly accepted drug sequencing strategy.

In addition to the ranking, the panelists discuss a range of topics, including:

  •     Sequencing therapies,
  •     Biomarkers,
  •     Progressive MS,
  •     Potent immunotherapy,
  •     Fingolimod – class effects or idiosyncratic,
  •     Minimally effective orals,
  •     Neuroregeneration/neurorepair, and
  •     Other mechanisms (e.g. CTLA4-Ig; inhibition of T-cell costimulation).

Transcripts of six qualitative interviews are included in the report.

Companies/partnerships discussed in this report: Acorda/Elan, Bayer Schering/Genzyme, Biogen Idec, Biogen Idec/Elan, Biogen Idec/Genentech/Roche, Biogen Idec/UCB, Boehringer Ingelheim/Exelixis, Cephalon, Glycominds, GlaxoSmithKline/Genmab, Lilly, Lilly/Daiichi Sankyo, Merck Serono, Merck Serono/Apitope, Merck Serono/Lpath, Merck Serono/ZymoGenetics, Novartis/Mitsubishi Tanabe Pharma, Novartis/Kyorin, Pfizer, PDL/Biogen Idec/Roche, Roche/Actelion, Sanofi-Aventis, Teva, and Teva/Sanofi-Aventis.

The full report may be purchased by contacting MedPredict.

About MedPredict
MedPredict maintains a proprietary database of over 1,000 global physician thought leaders. Based on primary interviews with these thought leaders, MedPredict publishes periodic therapeutic area reports to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and presentations, as well as clinical, regulatory and marketing activity.

For more information contact:
Elizabeth Mathews

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Elizabeth Mathews
Visit website